- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Therapeutic Areas
Publications and Presentations
Check out our publications and poster presentations.
September 2019
ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat + everolimus vs. placebo + E in patients with advanced/metastatic renal cell carcinomaEuropean Society for Medical Oncology
July 2019
May 2019
Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228American Society of Clinical Oncology
April 2019
Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73American Association of Cancer Research
June 2018
Phase 1 clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumorsAmerican Society of Clinical Oncology
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.